Indian Journal of Cancer Home 

REVIEW ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2022  |  Volume : 59  |  Issue : 1  |  Page : 4--11

Therapeutic approaches for relapsed/refractory adult acute lymphoblastic leukemia (ALL), a review on monoclonal antibodies and targeted therapies

Maryam S Hosseini1, Leila Jafari2, Amir Yami1, Ahmad Gharehbaghian1 
1 Department of Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences; Pediatric Cell and Gene Therapy Research Center, Gene, Cell and Tissue Research Institute, Tehran University of Medical Science, Tehran, Iran

Correspondence Address:
Ahmad Gharehbaghian
Department of Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran
Iran

Acute lymphoblastic leukemia (ALL) is the malignant transformation of lymphoid progenitors that affects both children and adults. Although the outcome of pediatric patients has been improved dramatically, there are still many challenges in the treatment of adults. Patients with primary resistant or relapsed disease have the worst outcome and despite the administration of intensified multi-agents chemotherapies, the outcome of this group remains very poor. Accordingly, the development of novel therapeutic options is considered necessary. Having a comprehensive insight into the pathophysiology of ALL and aberrant signaling pathways is crucial for introducing effective targeted therapies. Combination therapies with new drugs and innovative targeted therapies with the aim of affecting the main aberrant signaling pathways in the disease are considered as new approaches. Here we tried to have a comprehensive review on the potential molecular targets in the treatment of refractory/relapsed ALL and the current therapeutic agents.


How to cite this article:
Hosseini MS, Jafari L, Yami A, Gharehbaghian A. Therapeutic approaches for relapsed/refractory adult acute lymphoblastic leukemia (ALL), a review on monoclonal antibodies and targeted therapies.Indian J Cancer 2022;59:4-11


How to cite this URL:
Hosseini MS, Jafari L, Yami A, Gharehbaghian A. Therapeutic approaches for relapsed/refractory adult acute lymphoblastic leukemia (ALL), a review on monoclonal antibodies and targeted therapies. Indian J Cancer [serial online] 2022 [cited 2022 Jun 24 ];59:4-11
Available from: https://www.indianjcancer.com/article.asp?issn=0019-509X;year=2022;volume=59;issue=1;spage=4;epage=11;aulast=Hosseini;type=0